← Back to all articles
PharmacologyPubMed Verified

Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca

McKenna DJ, Towers GHN, Abbott F

Journal of Ethnopharmacology (1984)

Preclinical / in vitro
Abstract

Foundational study establishing the pharmacological basis of ayahuasca: beta-carbolines from B. caapi inhibit MAO, allowing DMT from P. viridis to be orally active.

Citations650
Study TypePreclinical / in vitro
MAO inhibitorsbeta-carbolinestryptaminepharmacological basis
DOI: 10.1016/0378-8741(84)90003-5View on PubMed

Related Articles

Pharmacology

Neuroprotective potential of ayahuasca and untargeted metabolomics analyses: applicability to Parkinson's disease

Katchborian-Neto A, Santos MFC et al.

Journal of Ethnopharmacology, 2020
Pharmacology

Psychoactive substances of natural origin: toxicological aspects, therapeutic properties and analysis in biological samples

Goncalves J, Luis A et al.

Molecules, 2021
Pharmacology

Pharmacokinetics of hoasca alkaloids in healthy humans

Callaway JC, McKenna DJ et al.

Journal of Ethnopharmacology, 1999
Pharmacology

Dimethyltryptamine and harmine, components of ayahuasca, prevented cocaine-induced apoptosis in SH-SY5Y human neuroblastoma cells

Salles G, de Carvalho Alves I et al.

Archives of Toxicology, 2025